TrialHuman vaccines & immunotherapeutics2019

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.

MMR-158 Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.